DE69529084D1 - Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme - Google Patents

Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme

Info

Publication number
DE69529084D1
DE69529084D1 DE69529084T DE69529084T DE69529084D1 DE 69529084 D1 DE69529084 D1 DE 69529084D1 DE 69529084 T DE69529084 T DE 69529084T DE 69529084 T DE69529084 T DE 69529084T DE 69529084 D1 DE69529084 D1 DE 69529084D1
Authority
DE
Germany
Prior art keywords
recording
antibody fragment
reduced renal
modified radio
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69529084T
Other languages
English (en)
Other versions
DE69529084T2 (de
Inventor
L Griffiths
J Hansen
Habibe Karacay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DE69529084D1 publication Critical patent/DE69529084D1/de
Publication of DE69529084T2 publication Critical patent/DE69529084T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69529084T 1994-09-20 1995-09-18 Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme Expired - Lifetime DE69529084T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/309,319 US5670132A (en) 1994-09-20 1994-09-20 Modified radioantibody fragments for reduced renal uptake
PCT/US1995/011406 WO1996009325A1 (en) 1994-09-20 1995-09-18 Modified radioantibody fragments for reduced renal uptake

Publications (2)

Publication Number Publication Date
DE69529084D1 true DE69529084D1 (de) 2003-01-16
DE69529084T2 DE69529084T2 (de) 2003-08-21

Family

ID=23197701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529084T Expired - Lifetime DE69529084T2 (de) 1994-09-20 1995-09-18 Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme

Country Status (11)

Country Link
US (1) US5670132A (de)
EP (1) EP0784634B1 (de)
JP (1) JPH10508832A (de)
AT (1) ATE229035T1 (de)
AU (1) AU3674995A (de)
CA (1) CA2200482C (de)
DE (1) DE69529084T2 (de)
DK (1) DK0784634T3 (de)
ES (1) ES2188671T3 (de)
IL (1) IL115255A (de)
WO (1) WO1996009325A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
PT968291E (pt) 1997-02-21 2004-06-30 Genentech Inc Conjugados de fragmento de anticorpo e polimero
EP0979102A4 (de) 1997-04-30 2005-11-23 Enzon Inc Einzelsträngige polypeptide modifiziert durch polyalkylenoxid
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6773916B1 (en) * 1999-01-05 2004-08-10 The Flinders University Of South Australia Agents and methods for treatment and diagnosis of ocular disorders
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
EP2316494A1 (de) * 2000-06-02 2011-05-04 Board Of Regents, The University Of Texas Ethylenedicysteine (EC)-Neomycin Konjugate und deren Verwendung in Imaging
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US20040143094A1 (en) * 2003-02-10 2004-07-22 Alena Donda Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
US20040068100A1 (en) * 2001-05-24 2004-04-08 Jean-Pierre Mach Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
EP1527346B1 (de) * 2002-08-07 2011-06-08 Ablynx N.V. Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
DE10237317B4 (de) * 2002-08-15 2010-04-08 3M Espe Ag Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
KR101086690B1 (ko) * 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
EP2390270A1 (de) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutische Polypeptide, Homologe davon, Fragmente davon und Verwendung bei modulierender plättchenvermittelter Aggregation
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20050214286A1 (en) * 2004-01-27 2005-09-29 University Of Southern California Polymer-bound antibody cancer therapeutic agent
EP1600141B1 (de) * 2004-05-24 2013-04-17 3M Deutschland GmbH Zusammensetzungen mit kollagenolytisch aktivem Enzym zur Behandlung von Karies
CA2593328C (en) * 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
US7807162B2 (en) * 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
EP1754464A1 (de) * 2005-08-17 2007-02-21 3M Innovative Properties Company Enzym-haltige Zusammensetzung für den dentalen Gebrauch
PT1986612E (pt) * 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP3936116A1 (de) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rekombinanten vwf enthaltende formulierungen
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
PT2349314E (pt) * 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
JP2014525904A (ja) 2011-06-28 2014-10-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
EP2863941B1 (de) 2012-03-02 2018-12-19 Shire Human Genetic Therapies, Inc. Velaglucerase zur behandlung von morbus gaucher typ iii
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
EP2994491A4 (de) 2013-05-10 2016-12-07 Whitehead Inst Biomedical Res In-vitro-herstellung von erythrozyten mit sortasefähigen proteinen
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
ES2941968T3 (es) * 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Marcaje de anticuerpos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5328679A (en) * 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5128119A (en) * 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
ATE172879T1 (de) * 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1991017440A1 (en) * 1990-05-07 1991-11-14 Immunomedics, Inc. Improved method for radiolabeling monovalent antibody fragments
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon

Also Published As

Publication number Publication date
ATE229035T1 (de) 2002-12-15
EP0784634B1 (de) 2002-12-04
WO1996009325A1 (en) 1996-03-28
IL115255A (en) 1999-08-17
IL115255A0 (en) 1995-12-31
EP0784634A4 (de) 1999-08-04
EP0784634A1 (de) 1997-07-23
ES2188671T3 (es) 2003-07-01
DK0784634T3 (da) 2003-03-10
DE69529084T2 (de) 2003-08-21
US5670132A (en) 1997-09-23
JPH10508832A (ja) 1998-09-02
CA2200482C (en) 2001-01-30
AU3674995A (en) 1996-04-09
CA2200482A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
DE69529084D1 (de) Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme
HUP1600016A2 (en) Antibody molecules having specificity for human tumor necrosis factor alpha and use thereof
KR970702882A (ko) 암치료 및 암탐지를 위한 종양세포 생성 단백질의 모노클로날 항체(monoclonal antibody to oncofetal protein for treating and detecting cancer)
AU1707800A (en) Token based source file compression/decompression and its application
ZA811384B (en) Labeled antibodies and antibody fragments specific to tumor-associated markers, compositions thereof and use thereof in tumor localization an therapy
BR0112111A (pt) Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
NZ332566A (en) Antigen binding fragments that specifically detect cancer cells
ME00783B (me) Kit za radioobilježavanje proteina sa itrijumom-90
EE03778B1 (et) Vähivaktsiin ja selle valmistamismeetod
EP0163304A3 (de) Menschliche monoklonale Antikörper gegen Zwischenfäden
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use
DE59610754D1 (de) Vereinfachte herstellung bispezifischer antikörperfragmente
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
CA2067797A1 (en) Production and use of human nm23 protein and antibodies therefor
MXPA04004658A (es) Anticuerpos monoclonales especificos para tumores.
HUP0100780A2 (hu) Új dezintegrin metalloproteáz, mutánsai, fragmentumai és hasonlók alkalmazása
AU2002215219A1 (en) Radiosensitivity enhancers in radiotherapy for cancer and nucleic acids and proteins enhancing radiosensitivity
ES2092960A1 (es) Gen de la proteina 1 de union a transferrina (tbp1) de actinobacillus pleuropneumoniae, utilizacion de esta en la preparacion de productos para la vacunacion contra la pleuroneumonia y en reactivos de diagnostico.
ITRM930535A0 (it) Metodo per la evidenziazione in vitro di marcatori tumorali da campioni tiroidei e kit per la sua realizzazione.
AU2228299A (en) Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
KR960022620U (ko) 간접형광항체법에 사용되는 커버슬립의 분획기구
NO914119D0 (no) Monoklonalt antistoff for differensiering av platecellekarsinom-antigener og fremgangsmaate for dets anvendelse
SE9503044D0 (sv) Antibodies for use in cancer therapy and diagnosis
KR970024252U (ko) 고정이 용이한 고정보울트

Legal Events

Date Code Title Description
8364 No opposition during term of opposition